Citadel Advisors’s Braskem BAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-230,600
Closed -$5.95M 9157
2019
Q1
$5.95M Buy
+230,600
New +$6.38M ﹤0.01% 2754
2017
Q3
Sell
-9,700
Closed -$201K 7513
2017
Q2
$201K Sell
9,700
-15,600
-62% -$322K ﹤0.01% 6561
2017
Q1
$515K Buy
+25,300
New +$532K ﹤0.01% 4970

Other funds holding BAK

Citadel Advisors's BAK Position: Q1 2026 in Review

Citadel Advisors sold out of Braskem (BAK) in Q1 2026, closing a stake of 59,781 shares — an estimated $176K sold.

Citadel Advisors first reported a position in BAK in Q2 2014 and held it in 27 quarters. The position peaked at $6.98M in Q2 2017. 64 funds tracked by Wall St. Rank hold BAK as of Q1 2026.

  • Citadel Advisors reported no remaining Braskem position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 59,781 Braskem shares in Q1 2026, an estimated $176K.
  • Citadel Advisors first reported a position in Braskem in Q2 2014 and held it in 27 quarters.
  • Citadel Advisors's Braskem position peaked at $6.98M in Q2 2017.
  • 64 funds tracked by Wall St. Rank held Braskem as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.